The Minimal Residual Disease Market represents a critical segment in the evolving landscape of cancer diagnostics and precision medicine. The Minimal Residual Disease Market is characterized by a blend of established diagnostic companies and innovative startups focusing on hematologic and solid tumor diagnostics.

 

DelveInsight’s “Minimal Residual Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Minimal Residual Disease, historical and forecasted epidemiology as well as the Minimal Residual Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Discover Key Insights into the Minimal Residual Disease Market with DelveInsight’s In-Depth Report @ Minimal Residual Disease Market Size

 

Key Takeaways from the Minimal Residual Disease Market Report

• In November 2024:- Pfizer- The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
• According to the statistics published by the American Cancer Society 2022, 34,470 new cases of multiple myeloma in the United States in 2022.
• About 6,660 new cases of acute lymphocytic leukemia (ALL) in 2022.
• As per the statistics published by the Leukemia and Lymphoma Society, in 2021, 90,390 new lymphoma cases were expected to be diagnosed in patients in the United States, of which 8,830 cases would be of Hodgkin lymphoma and 81,560 cases of non-Hodgkin lymphoma.
• The leading Minimal Residual Disease Companies such as Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology, and others
• Prominent Minimal Residual Disease Therapies such as ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis, and others

 

Stay ahead in the Minimal Residual Disease Therapeutics Market with DelveInsight’s Strategic Report @ Minimal Residual Disease Market Outlook

 

Minimal Residual Disease Epidemiology Segmentation:

• Total Prevalence of Minimal Residual Disease
• Prevalent Cases of Minimal Residual Disease by severity
• Gender-specific Prevalence of Minimal Residual Disease
• Diagnosed Cases of Episodic and Chronic Minimal Residual Disease

 

Download the report to understand which factors are driving Minimal Residual Disease epidemiology trends @ Minimal Residual Disease Prevalence

 

Minimal Residual Disease Market Dynamics

The dynamics of the minimal residual disease market is expected to change in the coming years. Several organizations and companies, including the European Scientific Foundation for Laboratory Hemato Oncology (ESLHO), the Leukemia and Lymphoma Society (LLS), and European LeukemiaNet (ELN), are raising awareness about the disease, which may result in a larger patient pool. Moreover, recent advances in high-throughput molecular genetics technologies, such as next-generation sequencing (NGS), may now provide a novel approach to detecting MRD.

 

Minimal Residual Disease Therapies and Companies

• ClonoSEQ: Adaptive Biotechnologies
• PhasED-Seq: Foresight Diagnostics
• Targeted Locus Amplification (TLA) technology: Cergentis B.V.
• MRDx BCR-ABL Test: ICON plc
• TRUPCR® PML-RARA: 3B BlacBio Biotech
• Signatera: Natera
• Leukemia Fusion Gene One-Step Detection Kits: EntroGen
• CBFB/MYH11 inv(16): Quest Diagnostics
• Seq-MRD: ImmuQuad
• PhasED-Seq: Foresight Diagnostics
• Targeted Locus Amplification (TLA) technology: Cergentis B.V.
• TRUPCR® PML-RARA: 3B BlacBio Biotech
• CBFB/MYH11 inv(16): Quest Diagnostics
• LymphoTrack: Invivoscribe Inc.
• Biocartis: Idylla Technology

 

Get In-Depth Knowledge on Minimal Residual Disease Market Trends and Forecasts with DelveInsight @ Minimal Residual Disease Treatment Market

 

Table of Content

1. Key Insights

2. Executive Summary of Minimal Residual Disease

3. Competitive Intelligence Analysis for Minimal Residual Disease

4. Minimal Residual Disease: Market Overview at a Glance

5. Minimal Residual Disease: Disease Background and Overview

6. Minimal Residual Disease Patient Journey

7. Minimal Residual Disease Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Minimal Residual Disease Unmet Needs

10. Key Endpoints of Minimal Residual Disease Treatment

11. Minimal Residual Disease Marketed Products

12. Minimal Residual Disease Emerging Therapies

13. Minimal Residual Disease: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Minimal Residual Disease Market Outlook

16. Access and Reimbursement Overview of Minimal Residual Disease

17. KOL Views

18. Minimal Residual Disease Market Drivers

19. Minimal Residual Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/